Literature DB >> 20029615

E14-F55 combination in M2 protein: a putative molecular determinant responsible for swine-origin influenza A virus transmission in humans.

Chungen Pan1, Shibo Jiang.   

Abstract

The species-specific signatures of the swine-origin influenza A (H1N1) virus (S-OIV), which caused the current influenza pandemic, have not been well defined. By comparing the protein sequences of S-OIVs with those of swine, avian and human influenza viruses, we found that that almost all human IAVs and those causing influenza pandemics, including the 2009 S-OIVs, had a combination of glutamic acid (E) residue at position 14 and phenylalanine (F) residue at position 55 in their M2 protein, while only 22% and 4% of the swine and avian IAVs had the E14-F55 combination. These finding suggests that E14-F55 combination in the M2 protein of S-OIV may be a molecular determinant associated with its human-to-human transmission.

Entities:  

Year:  2009        PMID: 20029615      PMCID: PMC2762779          DOI: 10.1371/currents.RRN1044

Source DB:  PubMed          Journal:  PLoS Curr        ISSN: 2157-3999


Introduction

In mid-June of 2009, the World Health Organization declared the first influenza pandemic of the 21st century (www.who.int), which was caused by a novel swine-origin influenza A H1N1 virus (S-OIV) [1]. Several groups [1] [2] [3] [4] have extensively analyzed the gene sequences of the S-OIV strains, but they could not identify any molecular features previously shown to confer increased human-to-human transmissibility, suggesting that there might be some as yet unrecognized molecular determinants responsible for transmission of S-OIV in humans . By comparing the sequences of proteins of avian and human influenza A viruses (IAVs), Shih’s group previously identified a number of species-specific signatures of these viruses [5] . Most recently, Huang and colleagues examined the amino acid sequences of S-OIV A (H1N1) at these signature positions and found that most of the S-OIV protein sequences were avian-like signatures, although a few of them had changed from avian- to human-like signatures[6]. Here we used a different approach to identify the potential species-specific signatures in S-OIV A (H1N1) by searching for both single and combined mutations, considering that some single mutations by themselves may not have a significant effect, but a combination of multiple mutations may have detrimental impact on viral transmissibility [7].

Material and Methods

From the NCBI website (http://www.ncbi.nlm.nih.gov/genomes/FLU), we downloaded the sequences of ten proteins (HA, NA, PB1, PB2, PA, NP, NS1, NS2, M1 and M2) of human IAVs (3114 sequences), swine IAVs (139 sequences) and avian IAVs (1658 sequences), as well as those that caused the influenza A pandemics in 1918-1919 (H1N1)(2 sequences), 1957-1963 (H2N2)(23 sequences), 1968-1970 (H3N2)(57 sequences) and 2009 (H1N1)(803 sequences) [8]. We performed multiple alignments by using the ClustalX multiple sequence alignment program 1.83 [9].

Results and Discussion

We identified 159 amino acid residues in the ten proteins of human IAVs that were different from those at the corresponding positions in the proteins of avian and swine IAVs. Most of these residues in the proteins of 2009 S-OIVs are identical to those in avian and swine IAVs. Interestingly, however, two residues at positions 14 and 55 in the M2 protein of the 2009 S-OIVs are identical to human IAVs, i.e., glutamic acid at position 14 (E14) and phenylalanine at position 55 (F55) , while most swine and avian IAVs contain glycine at position 14 (G14) and leucine at position (L55), respectively, although the entire M2 protein of S-OIVs had higher sequence identity with that of animal IAVs than human IAVs (Figure 1). By comparing the frequency of these two amino acid residues in all IAVs analyzed, we found that 100% of 2009 S-OIVs and >99% of human IAVs had E14 and F55 in the M2 protein. However, about 26% and 49% of the swine IAVs, and 63% and 29% of the avian IAVs had E14 and F55, respectively (Table 1). More interestingly, only 22% and 4% of the swine and avian IAVs had the E14-F55 combination, whereas 98.8% of human IAVs and 100% of the 2009 S-OIVs and those causing the 1957 and 1968 influenza pandemics had the E14-F55 combination  (Table 1). But the frequency (%) of the E14-F55 combination in M2 protein of the IAVs causing 1918 influenza pandemic cannot be calculated because there are only 2 related sequences available. Our results suggest that the E14-F55 combination may be a molecular determinant responsible for human-to-human transmission of IAVs. It was reported that the M protein of S-OIV was derived from the Eurasian swine IAVs [3], in which the predominant residues at positions 14 and 55 are glycine (G14) and leucine (L55), respectively. Therefore, the double mutation of G14→E and L55→F may contribute to the increased human transmissibility of S-OIVs. M2 protein, which consists of an extracellular domain (M2e: aa 1-24), a transmembrane domain (TM: aa 25-43) and a cytoplasmic tail (CT: aa 44-97), plays important roles in the life cycle of IAV, as it forms disulfide-linked homotetrameric helix bundles to provide an acidified environment for virus uncoating and maturation by regulating the pH within the virion, thereby serving as a target for anti-influenza drugs [10]. It also regulates the pH of the trans-Golgi vesicles in IAV-infected cells to prevent the low pH-induced conformational change of the HA from occurring during its maturation [11] .  The fragment of residues 51–59 in the CT of M2 protein forms amphipathic helice [12] , an important part of the homotetrameric ion channel. Interestingly, the amino acid residue at the position of 55 is located in the middle of the amphipathic helice. The aromatic ring of F55 in ion channel may provide preferable environment for uncoating and maturation of human IAVs, while the aliphatic side chain of L55 in ion channel may give an environment suitable for the replication of swine IAVs (Figure 2). M2e contains a conservative epitope that can induce antibodies capable of inhibiting virus budding and maturation and in vivo protection against both homologous and heterologous influenza viruses. Several M2e-based “universal” influenza vaccines are under preclinical and clinical development [5] [13] [14] . Liu et al have shown that the region of aa 10-20 in M2e protein confers the host restriction specificities [15] . It was reported that the amino acid residues at positions 16, 20, 28, 55, and 78 in M2 are associated with host specificity [16] . Since the functionality of M2 protein is determined by both M2e and CT sequences [12] , the combined mutation of residues in M2e, e.g., E14, and CT, e.g., F55, may have synergistic effect on the change of structure and function of the M2 protein as well as the shift of host restriction specificity, possibly rendering the virus more effective in infecting human cells. If this hypothesis is confirmed, E14, F55 and E14-F55 combination can serve as species-specific signatures for predicting cross-species transmission of the newly emerged IAVs and these sites may serve as targets for developing anti-IAV therapeutics and vaccines. Table 1. The frequency of E14, F55 and the E14-F55 combination in the M2 protein of human, swine, avian and pandemic IAVs *The frequency (%) cannot be calculated because there are only 2 related sequences available. Figure 1. Amino acid sequence alignment of M2 proteins from the swine-original (H1N1) influenza virus (S-OIV) and other influenza A viruses. Figure 2. Top and side views of the homotetrameric helix bundles formed by CT of M2 protein from the 2009 S-OIV (A and C) and Eurasia swine IAV (B and D), respectively.

Acknowledgments

The authors thank Mr. Byron Cheung for data collection.

Funding information

C. Pan was partially supported by an Exchanging Scholarship from China Scholarship Council of the Ministry of Education of China.

Competing interests

The authors have declared that no competing interests exist.
InfluenzaA virusesFrequency (%)
E14F55E14-F55
S-OIV H1N1 721/721 (100) 721/721 (100) 721/721 (100)
Swine 36/139 (25.9) 66/135 (48.9) 29/135 (21.5)
H1N112/60 (20.0)22/60 (36.7)10/60 (16.7)
H3N224/79 (30.4)44/75 (58.7)19/75 (35.3)
Avian 1041/1658 (62.8) 471/1647 (28.6) 59/1647 (3.6)
H1N11/42 (2.4)2/41 (4.9)1/41 (2.4)
H2N20/4 (0)0/4 (0)0/4 (0)
H3N21/53 (1.9)14/53 (26.4)0/53 (0)
H5N1995/1064 (93.5)28/1062 (2.6)18/1062 (1.7)
H9N244/495 (8.9)427/487 (87.8)40/487 (8.2)
Human 3081/3114 (98.9) 3105/3114 (99.7) 3076/3114 (98.8)
H1N1978/983 (99.5)978/983 (99.5)977/983 (99.4)
H3N22103/2131 (98.7)2127/2131 (99.8)2099/2131 (98.5)
Past pandemic 81/81 (100) 80/82 (97.6) 80/82 (97.6)
 1968 H3N257/57 (100)57/57 (100)57/57 (100)
 1957 H2N223/23 (100)23/23 (100)23/23 (100)
 1918 H1N11/1* 0/2*  0/2*
  16 in total

1.  The signature features of influenza pandemics--implications for policy.

Authors:  Mark A Miller; Cecile Viboud; Marta Balinska; Lone Simonsen
Journal:  N Engl J Med       Date:  2009-05-07       Impact factor: 91.245

2.  Stability and function of the influenza A virus M2 ion channel protein is determined by both extracellular and cytoplasmic domains.

Authors:  Tatiana Betakova; Alan J Hay
Journal:  Arch Virol       Date:  2008-12-10       Impact factor: 2.574

3.  The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools.

Authors:  J D Thompson; T J Gibson; F Plewniak; F Jeanmougin; D G Higgins
Journal:  Nucleic Acids Res       Date:  1997-12-15       Impact factor: 16.971

4.  Sequence comparison between the extracellular domain of M2 protein human and avian influenza A virus provides new information for bivalent influenza vaccine design.

Authors:  Wanli Liu; Peng Zou; Jian Ding; Yun Lu; Ying-Hua Chen
Journal:  Microbes Infect       Date:  2004-12-25       Impact factor: 2.700

5.  Structure and mechanism of the M2 proton channel of influenza A virus.

Authors:  Jason R Schnell; James J Chou
Journal:  Nature       Date:  2008-01-31       Impact factor: 49.962

Review 6.  Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments.

Authors:  Michael Schotsaert; Marina De Filette; Walter Fiers; Xavier Saelens
Journal:  Expert Rev Vaccines       Date:  2009-04       Impact factor: 5.217

Review 7.  Novel swine-origin influenza virus A (H1N1): the first pandemic of the 21st century.

Authors:  Luan-Yin Chang; Shin-Ru Shih; Pei-Lan Shao; Daniel Tsung-Ning Huang; Li-Min Huang
Journal:  J Formos Med Assoc       Date:  2009-07       Impact factor: 3.282

8.  Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans.

Authors:  Rebecca J Garten; C Todd Davis; Colin A Russell; Bo Shu; Stephen Lindstrom; Amanda Balish; Wendy M Sessions; Xiyan Xu; Eugene Skepner; Varough Deyde; Margaret Okomo-Adhiambo; Larisa Gubareva; John Barnes; Catherine B Smith; Shannon L Emery; Michael J Hillman; Pierre Rivailler; James Smagala; Miranda de Graaf; David F Burke; Ron A M Fouchier; Claudia Pappas; Celia M Alpuche-Aranda; Hugo López-Gatell; Hiram Olivera; Irma López; Christopher A Myers; Dennis Faix; Patrick J Blair; Cindy Yu; Kimberly M Keene; P David Dotson; David Boxrud; Anthony R Sambol; Syed H Abid; Kirsten St George; Tammy Bannerman; Amanda L Moore; David J Stringer; Patricia Blevins; Gail J Demmler-Harrison; Michele Ginsberg; Paula Kriner; Steve Waterman; Sandra Smole; Hugo F Guevara; Edward A Belongia; Patricia A Clark; Sara T Beatrice; Ruben Donis; Jacqueline Katz; Lyn Finelli; Carolyn B Bridges; Michael Shaw; Daniel B Jernigan; Timothy M Uyeki; Derek J Smith; Alexander I Klimov; Nancy J Cox
Journal:  Science       Date:  2009-05-22       Impact factor: 47.728

9.  In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses.

Authors:  Yasushi Itoh; Kyoko Shinya; Maki Kiso; Tokiko Watanabe; Yoshihiro Sakoda; Masato Hatta; Yukiko Muramoto; Daisuke Tamura; Yuko Sakai-Tagawa; Takeshi Noda; Saori Sakabe; Masaki Imai; Yasuko Hatta; Shinji Watanabe; Chengjun Li; Shinya Yamada; Ken Fujii; Shin Murakami; Hirotaka Imai; Satoshi Kakugawa; Mutsumi Ito; Ryo Takano; Kiyoko Iwatsuki-Horimoto; Masayuki Shimojima; Taisuke Horimoto; Hideo Goto; Kei Takahashi; Akiko Makino; Hirohito Ishigaki; Misako Nakayama; Masatoshi Okamatsu; Kazuo Takahashi; David Warshauer; Peter A Shult; Reiko Saito; Hiroshi Suzuki; Yousuke Furuta; Makoto Yamashita; Keiko Mitamura; Kunio Nakano; Morio Nakamura; Rebecca Brockman-Schneider; Hiroshi Mitamura; Masahiko Yamazaki; Norio Sugaya; M Suresh; Makoto Ozawa; Gabriele Neumann; James Gern; Hiroshi Kida; Kazumasa Ogasawara; Yoshihiro Kawaoka
Journal:  Nature       Date:  2009-08-20       Impact factor: 49.962

10.  Genomic signatures of human versus avian influenza A viruses.

Authors:  Guang-Wu Chen; Shih-Cheng Chang; Chee-keng Mok; Yu-Luan Lo; Yu-Nong Kung; Ji-Hung Huang; Yun-Han Shih; Ji-Yi Wang; Chiayn Chiang; Chi-Jene Chen; Shin-Ru Shih
Journal:  Emerg Infect Dis       Date:  2006-09       Impact factor: 6.883

View more
  5 in total

Review 1.  Two years after pandemic influenza A/2009/H1N1: what have we learned?

Authors:  Vincent C C Cheng; Kelvin K W To; Herman Tse; Ivan F N Hung; Kwok-Yung Yuen
Journal:  Clin Microbiol Rev       Date:  2012-04       Impact factor: 26.132

2.  Avian Influenza Virus with Hemagglutinin-Neuraminidase Combination H8N8, Isolated in Russia.

Authors:  Mariya V Sivay; Kirill A Sharshov; Mary Pantin-Jackwood; Vladimir V Muzyka; Alexander M Shestopalov
Journal:  Genome Announc       Date:  2014-06-05

Review 3.  Roles of the hemagglutinin of influenza A virus in viral entry and development of antiviral therapeutics and vaccines.

Authors:  Shibo Jiang; Runming Li; Lanying Du; Shuwen Liu
Journal:  Protein Cell       Date:  2010-05-08       Impact factor: 14.870

4.  H9N2 low pathogenic avian influenza in Pakistan (2012-2015).

Authors:  Dong-Hun Lee; David E Swayne; Poonam Sharma; Shafqat Fatima Rehmani; Abdul Wajid; David L Suarez; Claudio Afonso
Journal:  Vet Rec Open       Date:  2016-06-27

5.  Genetic and Antigenic Characteristics of Highly Pathogenic Avian Influenza A(H5N8) Viruses Circulating in Domestic Poultry in Egypt, 2017-2021.

Authors:  Ahmed Kandeil; Yassmin Moatasim; Ahmed El Taweel; Mohamed El Sayes; Adam Rubrum; Trushar Jeevan; Pamela P McKenzie; Richard J Webby; Mohamed A Ali; Ghazi Kayali; Rabeh El-Shesheny
Journal:  Microorganisms       Date:  2022-03-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.